(AZN) AstraZeneca - Ratings and Ratios
Oncology, Cardiovascular, Respiratory, Rare-Disease, Vaccines
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.08% |
| Yield on Cost 5y | 3.18% |
| Yield CAGR 5y | 2.33% |
| Payout Consistency | 96.5% |
| Payout Ratio | 35.9% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Value at Risk 5%th | 39.7% |
| Relative Tail Risk | -4.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.16 |
| Alpha | 29.79 |
| CAGR/Max DD | 0.48 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.492 |
| Beta | 0.410 |
| Beta Downside | 0.520 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.87% |
| Mean DD | 9.75% |
| Median DD | 9.69% |
Description: AZN AstraZeneca December 01, 2025
AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical firm headquartered in Cambridge, UK, that discovers, develops, manufactures, and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare-disease therapeutic areas. Its product roster includes blockbuster oncology agents such as Tagrisso and Imfinzi, metabolic drugs like Farxiga, and respiratory treatments such as Symbicort, sold through a network of distributors and local offices in the United Kingdom, United States, Europe, and Asia. The company has strategic partnerships with Tempus (oncology AI), IonQ (quantum-accelerated chemistry), CSPC (oral candidate discovery), and Revna Biosciences (lung-cancer therapy).
In FY 2023, AstraZeneca reported revenue of approximately $44.5 billion, driven by a 5% year-over-year increase in oncology sales and double-digit growth in its cardiovascular-renal portfolio, reflecting strong demand for Tagrisso and Farxiga. The firm’s pipeline features over 30 late-stage candidates, with Tagrisso-plus and Imfinzi-plus expected to sustain high-margin growth amid a sector-wide shift toward targeted cancer therapies. Macro-level drivers include an aging global population, rising prevalence of chronic diseases, and continued pressure on drug pricing, which together shape the company’s pricing strategy and R&D allocation.
For a deeper dive into AZN’s valuation metrics and forward-looking cash-flow projections, the ValueRay platform offers a concise analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 9.40b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.30 > 1.0 |
| NWC/Revenue: -7.08% < 20% (prev -3.46%; Δ -3.62% < -1%) |
| CFO/TA 0.13 > 3% & CFO 15.14b > Net Income 9.40b |
| Net Debt (24.52b) to EBITDA (17.94b): 1.37 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.12b) vs 12m ago 0.06% < -2% |
| Gross Margin: 82.28% > 18% (prev 0.81%; Δ 8147 % > 0.5%) |
| Asset Turnover: 52.99% > 50% (prev 48.80%; Δ 4.19% > 0%) |
| Interest Coverage Ratio: 8.30 > 6 (EBITDA TTM 17.94b / Interest Expense TTM 1.57b) |
Altman Z'' (< 1.1 .. > 2.6) 0.96
| A: -0.04 (Total Current Assets 29.94b - Total Current Liabilities 34.05b) / Total Assets 114.46b |
| B: 0.07 (Retained Earnings 8.21b / Total Assets 114.46b) |
| C: 0.12 (EBIT TTM 13.01b / Avg Total Assets 109.69b) |
| D: 0.16 (Book Value of Equity 10.64b / Total Liabilities 68.48b) |
| Altman-Z'' Score: 0.96 = BB |
ValueRay F-Score (Strict, 0-100) 79.45
| 1. Piotroski: 8.0pt |
| 2. FCF Yield: 3.53% |
| 3. FCF Margin: 19.18% |
| 4. Debt/Equity: 0.71 |
| 5. Debt/Ebitda: 1.37 |
| 6. ROIC - WACC: 7.11% |
| 7. RoE: 21.80% |
| 8. Revenue Trend: 87.65% |
| 9. EPS Trend: -16.66% |
What is the price of AZN shares?
Over the past week, the price has changed by -6.02%, over one month by -1.10%, over three months by +8.80% and over the past year by +36.01%.
Is AZN a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AZN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99 | 9.3% |
| Analysts Target Price | 99 | 9.3% |
| ValueRay Target Price | 105.8 | 16.9% |
AZN Fundamental Data Overview January 17, 2026
P/E Forward = 18.2482
P/S = 5.0135
P/B = 6.3507
P/EG = 1.0799
Revenue TTM = 58.13b USD
EBIT TTM = 13.01b USD
EBITDA TTM = 17.94b USD
Long Term Debt = 24.70b USD (from longTermDebt, last quarter)
Short Term Debt = 6.58b USD (from shortTermDebt, last quarter)
Debt = 32.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.52b USD (from netDebt column, last quarter)
Enterprise Value = 315.90b USD (291.42b + Debt 32.66b - CCE 8.18b)
Interest Coverage Ratio = 8.30 (Ebit TTM 13.01b / Interest Expense TTM 1.57b)
EV/FCF = 28.34x (Enterprise Value 315.90b / FCF TTM 11.15b)
FCF Yield = 3.53% (FCF TTM 11.15b / Enterprise Value 315.90b)
FCF Margin = 19.18% (FCF TTM 11.15b / Revenue TTM 58.13b)
Net Margin = 16.17% (Net Income TTM 9.40b / Revenue TTM 58.13b)
Gross Margin = 82.28% ((Revenue TTM 58.13b - Cost of Revenue TTM 10.30b) / Revenue TTM)
Gross Margin QoQ = 81.16% (prev 82.89%)
Tobins Q-Ratio = 2.76 (Enterprise Value 315.90b / Total Assets 114.46b)
Interest Expense / Debt = 1.07% (Interest Expense 349.0m / Debt 32.66b)
Taxrate = 21.86% (709.0m / 3.24b)
NOPAT = 10.16b (EBIT 13.01b * (1 - 21.86%))
Current Ratio = 0.88 (Total Current Assets 29.94b / Total Current Liabilities 34.05b)
Debt / Equity = 0.71 (Debt 32.66b / totalStockholderEquity, last quarter 45.89b)
Debt / EBITDA = 1.37 (Net Debt 24.52b / EBITDA 17.94b)
Debt / FCF = 2.20 (Net Debt 24.52b / FCF TTM 11.15b)
Total Stockholder Equity = 43.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.57% (Net Income 9.40b / Total Assets 114.46b)
RoE = 21.80% (Net Income TTM 9.40b / Total Stockholder Equity 43.11b)
RoCE = 19.18% (EBIT 13.01b / Capital Employed (Equity 43.11b + L.T.Debt 24.70b))
RoIC = 13.88% (NOPAT 10.16b / Invested Capital 73.23b)
WACC = 6.77% (E(291.42b)/V(324.08b) * Re(7.43%) + D(32.66b)/V(324.08b) * Rd(1.07%) * (1-Tc(0.22)))
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 84.18% ; FCFF base≈9.39b ; Y1≈10.59b ; Y5≈14.27b
Fair Price DCF = 97.02 (EV 325.32b - Net Debt 24.52b = Equity 300.80b / Shares 3.10b; r=6.77% [WACC]; 5y FCF grow 14.89% → 2.90% )
EPS Correlation: -16.66 | EPS CAGR: -47.17% | SUE: -4.0 | # QB: 0
Revenue Correlation: 87.65 | Revenue CAGR: 6.46% | SUE: 1.11 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.26 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=5.15 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+12.1% | Growth Revenue=+6.3%
Additional Sources for AZN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle